Cellectar regains Nasdaq compliance after filing restated financials and Form 10-Q

Cellectar Biosciences, Inc.

Received Nasdaq letter dated Oct 31, 2024 confirming compliance with Listing Rule 5250(c)(1).
Filed on Oct 29, 2024 restated audited financials for FY2022 and FY2023 and restated quarterly periods in 2022-2023.
Also filed restated Q1 2024 quarterly report (Form 10-Q/A) and regular Q2 2024 quarterly report (Form 10-Q).
Nasdaq noted the matter is now closed, removing delisting risk from late filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.